“In a world devastated by the COVID-19 pandemic and where rapidly mutating variants continue to emerge, it is a race for the scientific community to develop new therapies in a timely manner.”
“We are pleased to report that our research and development efforts have quickly paid off with our single B-cell technology, which has demonstrated neutralizing efficacy against the world’s most common and deadliest omicron variant,” said Juz -Hsiang Chiu, MD, CEO of AcadeMab.
Despite high vaccination rates worldwide, vaccines are only part of the treatment system to combat the scourge of COVID-19.
The Omicron variant has been shown to show remarkable resistance to most of the previously developed immunotherapies, such as bamlanivimab, developed by Eli Lilly, and the casirivimab-imdevimab antibody cocktail, developed by Regeneron Pharmaceuticals.
As a result, the Food and Drug Administration (FDA) has revoked or restricted emergency use authorizations (EUAs) for most therapeutic antibodies.
Studies conducted by AcadeMab have demonstrated high potency of their human monoclonal antibodies against the Omicron variant within 4 months.
In one of their studies, it was found that a human antibody showed the best ability to neutralize (IC50 = 11.4 and 4.3 ng/ml) in both Omicron variants BA.1 and BA.2, respectively.
“We have also seen broad-spectrum activity in our treatment against several circulating variants of concern (VOCs) announced by the World Health Organization.”
“Apart from its neutralizing efficacy against Omicron, this shows great potential to be a therapy of choice for patients infected with other COVID-19 variants alongside Omicron,” said Pao Yin ChiangPh.D., Principal Investigator of the Single B Cell Platform at AcadeMab.
The development of AcadeMab’s cutting-edge technology using single B-cell technology will be of immense benefit to a segment of high-risk individuals who cannot fully benefit from mere vaccination alone.
This includes those who are moderately to severely immunocompromised and do not have adequate immune responses despite COVID-19 vaccinations. It is estimated that approximately 2.7% of adults (or 7 million) in the US population are immunocompromised.
This breakthrough treatment will also benefit those who have a documented history of severe adverse reactions to existing COVID-19 vaccines or their components and are therefore unable to be vaccinated.
Parties interested in establishing a partnership and learning more about AcadeMab’s research can contact:
PR NAME: Miles yesPh.D., Director of Product Development
CONTACT NUMBER: +886-2789-1212 ext. 810
E-MAIL: [email protected]
SOURCE AcadeMab Biomedical Inc.
